Compare IDT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDT | ANAB |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | United States | United States |
| Employees | 1925 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2015 |
| Metric | IDT | ANAB |
|---|---|---|
| Price | $54.87 | $54.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $80.00 | $71.67 |
| AVG Volume (30 Days) | 123.2K | ★ 465.0K |
| Earning Date | 06-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | N/A | $52.14 |
| P/E Ratio | $15.10 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $45.72 | $17.11 |
| 52 Week High | $71.12 | $73.30 |
| Indicator | IDT | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 53.11 | 44.90 |
| Support Level | $50.71 | $53.46 |
| Resistance Level | $58.44 | $57.70 |
| Average True Range (ATR) | 1.98 | 2.43 |
| MACD | -0.07 | 0.12 |
| Stochastic Oscillator | 42.47 | 47.74 |
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).